1. Home
  2. Browse
  3. Practice
  4. Legal & Licensing
  5. Drug Withdrawals/Restricted Sale

Drug Withdrawals/Restricted Sale

76 - 90 of 155 Results
Sort Results:
Commentary: New Formulation: Oxecta (Oxycodone) October 2011
Chart: Fentanyl Products for Breakthrough Pain October 2011
Article: two new opioid formulations, Oxecta and Lazanda October 2011
Commentary: Actos (Pioglitazone) and Increased Risk of Bladder Cancer July 2011
Article: confusing the news about Avandia and Actos July 2011
Commentary: REMS for Long-Acting and Extended-Release Opioids June 2011
Article: A new Risk Evaluation and Mitigation Strategy (REMS) will aim to reduce the misuse of long-acting opioids June 2011
Article: About 500 Rx cough, cold, and allergy products will be taken off the market by September April 2011
Commentary: Safety of Using ADHD Stimulant Meds with Decongestants April 2011
Other: FDA listing of Unapproved Prescription Cough, Cold, and Allergy Products April 2011
Guideline: Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs (April 2008) April 2011
Chart: Alternatives to Unapproved Cough and Cold Meds April 2011
Guideline: Diagnosis and Management of ADHD (ICSI; March 2012) April 2011
Guideline: Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs (Correction) (June 2008) April 2011
Article: whether patients on stimulants for ADHD can take cough, cold, and allergy meds containing decongestants April 2011